Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial

Kosmidis, P.; Mylonakis, Nick; Nicolaides, C.; Kalophonos, C.; Samantas, Epaminontas; Boukovinas, J.; Fountzilas, George; Skarlos, Dimosthenis; Economopoulos, T.; Tsavdaridis, D.; Papakostas, Pavlos; Bacoyiannis, C.; Dimopoulos, Meletios Α.

doi:10.1200/jco.2002.12.112

Cited by 233 publications

(128 citation statements)

References 29 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…Standard premedication with dexamethasone at a dose of 20 mg given orally 12 and 6 h prior to paclitaxel infusion has been shown to prevent HSR in most cases (Weiss et al, 1990;Rowinsky and Donehower, 1995;Kintzel, 2001). Despite this premedication schedule, grade 3/4 HSR still occur in 1 -2% of patients (Kosmidis et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

et al. 2004

View full text Add to dashboard Cite

Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1-and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone.

show abstract

Section: Discussionmentioning

confidence: 99%

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The proportion of males varied within the range of 51%-93%. Most patients had stage IIIB or IV NSCLC; inoperable stage IIIA disease was also admitted in three studies [35,45,62], whereas stage IIIB disease was excluded in one trial [47].…”

Section: Patient Characteristicsmentioning

confidence: 99%

“…discontinued treatment early because of voluntary withdrawal or drug toxicity [32,35]. Finally, two studies published in abstract form excluded patients for whom data were not available and/or with insufficient follow-up [37,54].…”

Section: Patient Characteristicsmentioning

confidence: 99%

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Grossi¹,

Aita²,

Defferrari³

et al. 2009

The Oncologist

View full text Add to dashboard Cite

Background. The therapeutic equivalence of different third-generation agents in the first-line treatment of advanced non-small cell lung cancer (NSCLC) has long been accepted, although recent studies seem to suggest some superiority of gemcitabine-or docetaxel-containing regimens over other third-generation doublets.Objective. To assess the relative impact of different third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer by considering both response and progressive disease (PD) rates as outcome measures.Methods. Published and unpublished data were collected from randomized trials comparing a gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-containing regimen with one or more gemcitabine-, docetaxel-, vinorelbine-or paclitaxel-free combinations. For

show abstract

“…Moreover, the toxicity profile of cisplatin can influence the patients' quality of life. Several randomised phase III studies have demonstrated that nonplatinum-containing regimens have substantial efficacy against advanced/metastatic NSCLC with a more favourable toxicity profile than the corresponding cisplatin-based regimens (Douillard et al, 2001;Georgoulias et al, 2001Georgoulias et al, , 2005Kosmidis et al, 2002).…”

mentioning

confidence: 99%

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

et al. 2008

View full text Add to dashboard Cite

Ribonucleotide reductase subunits M1 (RRM1) and M2 (RRM2) are involved in the metabolism of gemcitabine (2 0 ,2 0 -difluorodeoxycytidine), which is used for the treatment of nonsmall cell lung cancer. The mRNA expression of RRM1 and RRM2 in tumours from lung adenocarcinoma patients treated with docetaxel/gemcitabine was assessed and the results correlated with clinical outcome. RMM1 and RMM2 mRNA levels were determined by quantitative real-time PCR in primary tumours of previously untreated patients with advanced lung adenocarcinoma who were subsequently treated with docetaxel/gemcitabine. Amplification was successful in 42 (79%) of 53 enrolled patients. Low levels of RRM2 mRNA were associated with response to treatment (Po 0.001). Patients with the lowest expression levels of RRM1 had a significantly longer time to progression (P ¼ 0.044) and overall survival (P ¼ 0.02) than patients with the highest levels. Patients with low levels of both RRM1 and RRM2 had a significantly higher response rate (60 vs 14.2%; P ¼ 0.049), time to progression (9.9 vs 2.3 months; P ¼ 0.003) and overall survival (15.4 vs 3.6; P ¼ 0.031) than patients with high levels of both RRM1 and RRM2. Ribonucleotide reductase subunit M1 and RRM2 mRNA expression in lung adenocarcinoma tumours is associated with clinical outcome to docetaxel/gemcitabine. Prospective studies are warranted to evaluate the role of these markers in tailoring chemotherapy.

show abstract

Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial

Abstract: The PG combination is as equally active and well tolerated as the PC combination in patients with advanced NSCLC.

Cited by 233 publications

References 29 publications

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

Contact Info

Product

Resources

About